DC+CIK联合化疗治疗晚期非小细胞肺癌的临床疗效评价

Clinical Effects of Administering Dendritic Cells and Cytokine Induced Killer Cells Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

目的:评价DC+CIK联合常规化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:选择70例晚期NSCLC患者进行研究,采用DC+CIK与常规化疗间隔进行的方案(生物治疗联合化疗组),对其进行生存分析;同时,对生物治疗联合化疗组、单纯常规化疗组同期配对NSCLC患者各61例,比较生物治疗联合化疗组与常规化疗对照组患者的生存率。结果:生物治疗联合常规化疗组患者预期1、2、3年生存率分别为59.6%、29.6%、21.80。生物治疗联合化疗组和单纯常规化疗组比较1年生存率分别为57.2%和37.3%,2年生存率分别为27.0%和10.1%(P<0.05)。结论:临床研究证实了DC+CIK联合常规化疗能够延长晚期NSCLC患者的生存期,提高患者的生存率和生活质量。

Objective： To evaluate the clinical effects of administering dendritic cells （DC） and cytokine induced killer cells （ClK） combined with chemotherapy in patients with advanced non-small cell lung cancer （NSCLC）. Methods： In the present clinical study, 70 advanced NSCLC patients received DC and CIK combined with chemotherapy at a given interval （biotherapy ＋ chemotherapy group）. The clinical therapeutic effect was observed and the survival rate was determined. A total of 61 NSCLC patients were selected for analysis in the chemotherapy group, and the survival rates were compared between the two groups. Results： For advanced NSCLC patients who received biotherapy combined with chemotherapy, the 1-, 2- and 3-year survival rates were 59.6%, 29.6%, and 21.8%, respectively. The 1-year survival rate in the biotherapy ＋ chemotherapy group and the chemotherapy group was 57.2% and 37.3%, respectively. The 2-year survival rate was 27.0% and 10.1%, respectively （P〈0.05）. Conclusion： Administration of DC and CIK combined with chemotherapy can prolong survival time in NSCLC patients and improve their quality of life.